Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

AtriCure director Maggie Yuen sold 3,500 shares (20% of her stake) at $38.42 per share on August 5, 2026, totaling $134,470. The sale occurred after the company reported strong Q2 results with 13% revenue growth to $154 million and expanded gross margins to 77%. The stock has surged over 60% since June lows, and analysts suggest the director sales likely reflect a post-earnings trading window opening rather than loss of confidence in the company.